Scarica l'app Stockscreener
6.17
9.13%
-0.62
Dopo l'orario di chiusura:
6.15
-0.02
-0.32%
Precedente Chiudi:
$6.79
Aprire:
$6.85
Volume 24 ore:
340.86K
Relative Volume:
0.53
Capitalizzazione di mercato:
$585.41M
Reddito:
-
Utile/perdita netta:
$-65.10M
Rapporto P/E:
-8.7184
EPS:
-0.7077
Flusso di cassa netto:
$-53.50M
1 W Prestazione:
-11.48%
1M Prestazione:
+1.48%
6M Prestazione:
+208.50%
1 anno Prestazione:
+471.30%
Intervallo 1D:
$6.16
$6.95
Intervallo di 1 settimana:
$6.16
$7.44
Portata 52W:
$0.97
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
Nome
Zura Bio Ltd
Settore
Industria
Telefono
858-247-0520
Indirizzo
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
6.17 | 585.41M | 0 | -65.10M | -53.50M | -0.7077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Iniziato | Wedbush | Outperform |
| 2024-11-04 | Iniziato | Leerink Partners | Outperform |
| 2024-09-05 | Iniziato | H.C. Wainwright | Neutral |
| 2024-05-03 | Iniziato | Piper Sandler | Overweight |
| 2023-10-10 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-08-25 | Iniziato | Oppenheimer | Outperform |
| 2023-06-22 | Iniziato | Guggenheim | Buy |
| 2023-06-14 | Iniziato | Chardan Capital Markets | Buy |
| 2023-05-24 | Iniziato | Raymond James | Strong Buy |
Mostra tutto
Zura Bio Ltd Borsa (ZURA) Ultime notizie
Atika Capital Management LLC Takes Position in Zura Bio Limited $ZURA - Defense World
Zura Bio’s Tibulizumab: First-in-Class Bispecific Antibody Targeting IL-17 and BAFF for Autoimmune Diseases (HS & SSc) – Pipeline, Trials, and Market Opportunity 2348 - Minichart
Zura Bio Updates Corporate Outlook on Lead Tibulizumab Program - TipRanks
Zura Bio updates corporate presentation, flags tibulizumab Phase 2 readouts, cash and shares - TradingView
Updated investor presentation furnished by Zura Bio (NASDAQ: ZURA) - Stock Titan
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio presents Phase 2 systemic sclerosis trial design By Investing.com - Investing.com Australia
Zura Bio launches Phase 2 TibuSURE trial in systemic sclerosis at Athens congress - Traders Union
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress - Yahoo Finance Singapore
Director Ajay Nirula files initial Form 3 for Zura Bio Ltd (ZURA) - Stock Titan
Major Zura Bio (ZURA) holder acquires 2M shares in registered deal - Stock Titan
Access Industries group lifts Zura Bio (ZURA) stake to 18.2% - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zura Bio heads to Miami for March 10-11 investor conferences - Stock Titan
Zura Bio to Participate in Upcoming Investor Conferences - Yahoo Finance
Zura Bio raises $144 million in public offering of shares By Investing.com - Investing.com South Africa
Zura Bio raises $144 million in public offering of shares - Investing.com India
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - ChartMill
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
Zura Bio prices $125M public offering at $6.25 per share - Investing.com Australia
Zura Bio (ZURA) launches $6.25 share and pre-funded warrant sale - Stock Titan
Zura Bio (NASDAQ: ZURA) seeks roughly $117M from 18.2M-share offering - Stock Titan
Zura Bio Prices Public Offering of 18.2 Million Shares - Intellectia AI
Zura Bio prices $125M public offering at $6.25 per share By Investing.com - Investing.com South Africa
Zura Bio launches public offering of Class A shares By Investing.com - Investing.com India
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - ChartMill
Director Mark Eisner files initial Form 3 for Zura Bio Ltd (ZURA) - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - Stock Titan
Zura Bio adds two immunology executives to board By Investing.com - Investing.com India
Zura Bio adds two immunology executives to board - Investing.com Australia
Zura Bio (ZURA) appoints Mark Eisner and Ajay Nirula to its board - Stock Titan
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors - ChartMill
Leaders behind four approved immunology drugs join Zura Bio board - Stock Titan
Risk Recap: What makes Zura Bio Limited stock attractive todayMarket Sentiment Report & Community Consensus Picks - baoquankhu1.vn
What risks investors should watch in Zura Bio Limited stockGDP Growth & Weekly High Momentum Picks - mfd.ru
Great Point discloses 3.8M Zura Bio (ZURA) shares in 13G/A - Stock Titan
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026 - Yahoo Finance
Why retail investors favor Zura Bio Limited stockWeekly Stock Recap & Daily Momentum Trading Reports - mfd.ru
ZURA PE Ratio & Valuation, Is ZURA Overvalued - Intellectia AI
Zura Bio Advances Tibulizumab Strategy in Autoimmune Diseases - TipRanks
Zura Bio Ltd Provides Updated Corporate Presentation - TradingView
This Nokia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Wedbush initiates coverage on Zura Bio stock with Outperform rating By Investing.com - Investing.com India
Wedbush initiates coverage on Zura Bio stock with Outperform rating - Investing.com
Wedbush Initiates Zura Bio at Outperform With $15 Price Target - marketscreener.com
Investment Report: Will Zura Bio Limited benefit from rising consumer demand2025 Short Interest & AI Driven Price Predictions - baoquankhu1.vn
Aug Update: Will Zura Bio Limited benefit from rising consumer demandJuly 2025 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit - ChartMill
Watch Zura Bio's Guggenheim biotech summit fireside chat live online - Stock Titan
Aug Sectors: What makes Zura Bio Limited stock attractive todayTrade Risk Assessment & Capital Protection Trading Alerts - baoquankhu1.vn
Zura Bio Ltd Azioni (ZURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):